Cash Flow Statement

Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Change in Interest Receivables Depreciation & Amortization (CF)Exchange Rate Effect Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Net Cash Flow Net Income Non-cash Items Other financing activities Share-based Compensation

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Kalaris Therapeutics (KLRS) Capital Expenditures (2019)

Kalaris Therapeutics (KLRS) has 1 years of Capital Expenditures data on record, last reported at $121000.0 in Q4 2019.